A randomized, non-comparative, multicenter, open-label, phase 2 study of Tarceva (Erlotinib) alone and of Tarceva plus VELCADE (bortezomib) for injection in patients with relapsed or refractory, locally advanced or metastatic non-small cell lung cancer.
Phase of Trial: Phase II
Latest Information Update: 16 Feb 2011
At a glance
- Drugs Bortezomib; Erlotinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Takeda Oncology
- 16 Feb 2011 Actual end date (1 Aug 2007) added as reported by ClinicalTrials.gov.
- 01 Aug 2009 Results have been reported in the Journal of Thoracic Oncology.
- 05 Jun 2007 Results have been published (1078763).